Table S1. Clinical and pathological characteristics of the validation cohort

	BLt1i0 biopsies (n=25)	BL≥t1i1 biopsies (n=31)	P-value
Recipient			
Age (yr)	51 ± 18	51 ± 15	0.96
Male gender	7 (28)	15 (48)	0.17
Time posttransplant (mo)	16 [1, 31]	11 [1, 76]	0.36
Scr at biopsy (mg/dL)	1.8 [1.5, 2.8]	2.5 [2.1, 3.1]	0.03
Positive DSA	0 (0)	0 (0)	1.00
Acute treatment (yes)	22 (88)	24 (77)	0.49
Biopsy scores			
Tubulitis (t)	1.0 ± 0	1.9 ± 0.6	<0.01
Interstitial inflammation (i)	0 ± 0	0.4 ± 0.6	<0.01
Intimal arteritis (v)	0 ± 0	0 ± 0	1.00
Tubular atrophy (ct)	1.4 ± 0.9	1.8 ± 0.7	0.13
Interstitial fibrosis (ci)	1.4 ± 0.9	1.8 ± 0.8	0.15
Fibrous intimal thickening (cv)	1.6 ± 0.8	2.0 ± 0.7	0.04
Arteriolar hyalinosis (ah)	1.6 ± 0.8	2.0 ± 0.8	0.08

Data are provided as mean ± standard deviation, *n* (%) or median [25th, 75th percentiles]. Comparisons were performed using t test, Fisher's exact test or Kruskall-Wallis. BLt1i0, patients with borderline changes suspicious for acute T-cell-mediated rejection (BL) with tubulitis score of 1 and interstitial inflammation score of 0; BL≥t1i1, patients with BL with tubulitis and interstitial inflammation score of at least 1; TCMR, T-cell-mediated rejection Scr, serum creatinine level; DSA, donor-specific antibody

Table S2. Risk estimates for death-censored graft failure level associated with the histological diagnosis

A. Nonrejection *vs.* BLt1i0 *vs.* BL≥t1i1 *vs.* TCMR

	Unadjusted		Adjustment 1[a]		Adjustment 2[b]	
	HR (95% CI)	*P*	HR (95% CI)	*P*	HR (95% CI)	*P*
NR	Ref	-	Ref	-	Ref	-
BLt1i0	0.8 (0.2–3.5)	0.75	0.9 (0.2–4.8)	0.87	0.8 (0.1–4.7)	0.82
BL≥t1i1	3.4 (1.0–11.8)	0.06	3.4 (0.7–16.9)	0.20	2.9 (0.6–15.2)	0.20
TCMR	1.7 (0.3–8.3)	0.53	2.0 (0.3–15.9)	0.50	1.1 (0.1–9.9)	0.93

[a] Adjusted for estimated glomerular filtration rate at biopsy, antirejection treatment and time posttransplant
[b] Adjusted for model 1 plus interstitial fibrosis/tubular atrophy (IFTA) sum score and donor specific antibody status
BL, borderline changes suspicious for the acute T-cell-mediated rejection category; NR, nonrejectors; TCMR, patients with T-cell-mediated rejection.

B. Pairwise comparison BLt1i0 *vs.* BL≥t1i1

	Unadjusted		Adjustment 1[a]		Adjustment 2[b]	
	HR (95% CI)	*P*	HR (95% CI)	*P*	HR (95% CI)	*P*
BLt1i0	Ref	-	Ref	-	Ref	-
BL≥t1i1	4.5 (1.5–13.7)	<0.01	3.8 (1.1–12.5)	0.03	3.1 (0.9–10.7)	0.07

[a] Adjusted for estimated glomerular filtration rate at biopsy, antirejection treatment and time posttransplant
[b] Adjusted for model 1 plus interstitial fibrosis/tubular atrophy (IFTA) sum score and donor specific antibody status
BLt1i0, patients with borderline changes suspicious for acute T-cell-mediated rejection (BL) and with a tubulitis score of 1 and an interstitial inflammation score of 0; BL≥t1i1, patients with BL with tubulitis and an interstitial inflammation score of at least 1.

Figure S1. **Kaplan-Meier plots for the composite endpoint of death-censored graft failure or doubling of the serum creatinine level for patients with BLt1i0, BL≥t1i1 in the validation cohort.**

Figure S2. Kaplan-Meier plots for the composite endpoint of death-censored graft failure or doubling of the serum creatinine levels using time from transplant as the reference.